Clinical trials

Patient receiving eye drops
#Clinical trials #Eye health #Healthcare #Therapeutics

Stuart Therapeutics Phase II clinical trial results of its dry eye candidate  

Stuart Therapeutics, a clinical stage, ophthalmic therapeutic development company, has announced the topline results of the first in human Phase II clinical trial for its lead drug candidate, ST-100 in patients with dry eye disease.   The trial  The clinical trial, conducted between June and October… Read More

#News

#Antibodies #Clinical trials #HIV #Immunology / Virology & Vaccines #mRNA

Experimental mRNA HIV vaccine is safe and shows promise in animals 

An experimental HIV vaccine based on mRNA shows promise in mice and non-human primates, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results The results, published in Nature Medicine, show that the novel vaccine was safe and… Read More

#News

#Clinical trials #Data #FDA #HIV

HIV prevention options expanded in the US 

The US Food and Drug Administration (FDA) has approved a long-acting HIV prevention medication for the first time.   The drug  Developed by ViiV Healthcare, the medicine is long-acting cabotegravir injected once every two months. The FDA has approved the medicine for use by adults and adolescents weighing… Read More

#News #Trending News

#Biopharmaceuticals #Biotherapeutics #Clinical trials

4D Pharma announces positive topline results for the treatment of asthma 

4D Pharma has announced positive topline results from Part A of its Phase I/II clinical trial of MRx-4DP0004, an orally-delivered single strain Live Biotherapeutic being developed for the treatment of asthma.  Part A  The Phase I/II trial is a multi-center, double-blind, placebo-controlled study in patients… Read More

#News

#Clinical trials #Covid-19 #Healthcare #Research

First UK trial to assess use of antivirals to treat Covid-19 set to begin 

The first clinical trial in the UK to investigate whether antiviral drugs could help reduce the severity of Covid-19 is due to start, led by the University of Oxford and delivered in Wales by Cardiff University in partnership with Public Health Wales and Health and Care Research Wales. Cardiff University staff… Read More

#News

Stomach pain
#Clinical trials #Irritable Bowel Syndrome #Microbiome

4D Pharma presents microbiome analyses from IBS Phase II clinical trial 

4D Pharma, a pharmaceutical company developing Live Biotherapeutic products (LBPs), has announced new faecal microbiome analyses from the completed Phase II trial of Blautix(R) (MRx1234) as a treatment for irritable bowel syndrome with constipation (IBS-C) or with diarrhoea (IBS-D). The new data was presented in an ePoster at Gastro 2021, held from December 9-11, 2021. … Read More

#News

#Biotechnology #Clinical trials #Drug design #Drug development #Rare disease #Therapeutics

Inside the rare disease centre which aims to accelerate biotech growth 

Emmes has launched a rare disease centre, Orphan Reach, to combine its health research across the public sector and biopharmaceutical industry. DDW’s Megan Thomas spoke with Thomas Ogorka, Managing Director of Orphan Reach: Emmes’ Rare Disease Center, about its potential.  MT: What will the expanded Orphan Reach centre add to what Emmes already offers?   TO: First and foremost, specialised rare… Read More

#Exclusive Content #News #Opinion

#Biotechnology #Clinical trials #Immunotherapy #Therapeutics #Tumours

Biotheus’ bifunctional therapeutic FDA-approved to enter Phase II studies 

Biotheus, a biotechnology company based in Zhuhai, China, with multiple clinical-stage assets under clinical development, has announced that its anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been approved by the United States Food and Drug Administration (FDA) for conducting clinical Phase II studies as part of an international multicentre clinical trial. … Read More

#News

#Clinical trials #Covid-19 #Drug discovery #Immunology / Virology & Vaccines #Omicron

Preclinical data of drug demonstrates protection against Omicron 

Following the approval of GlaxoSmithKline (GSK) and Vir Biotechnology’s Covid-19 drug Xevudy (sotrovimab), the companies have announced an update, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab.  … Read More

#Covid-19 #News

#Clinical trials #Drug development #Software

Community forum and resource hub launched to support clinical trials 

Formedix, a provider of clinical trial software solutions, has launched the Formedix ryze Community to provide customers with a location to collaborate, expand their knowledge and share information.  What does the platform do?  Through a range of tools, the ryze Community will support the pharmaceutical industry to streamline and enhance… Read More

#News

#Cancer research #Clinical trials #Drug therapy #Therapeutics

Phase I clinical study begins for patients with advanced liver cancer 

The National University Cancer Institute, Singapore (NCIS) and MiNA Therapeutics have dosed the first patients in an investigator-sponsored Phase I study of MiNA’s small activating RNA oligonucleotide, MTL-CEBPA, in combination with first-line standard of care, atezolizumab and bevacizumab, in patients with previously untreated, advanced hepatocellular carcinoma (HCC). Atezolizumab and bevacizumab are… Read More

#Cancer Research #News #Trending News

#Clinical trials #Drug development

Data suggests racial diversity underrepresented in clinical trials 

Phesi has analysed protocol design data and showed that Asian, Hispanic and Latino, Native Americans and Alaska natives, Native Hawaiians and other Pacific Islander patient subpopulations were all significantly and consistently underrepresented over the decade. Black and African American patients appear to have become better represented over the past decade.  The study  The data was… Read More

#News #Trending News #Trends & Analysis

#AI / data analytics / healthtech / informatics #Clinical trials #Drug discovery

First-in-Human Study of a novel drug discovered using AI platform 

Insilico Medicine, an artificial intelligence (AI)-driven drug discovery company, has announced that the first healthy volunteer has been dosed in a first-in-human microdose trial of ISM001-055.  What is ISM001-055?  ISM001-055 is a potentially first-in-class small molecule inhibitor of a novel biological target discovered by Pharma.AI, Insilico Medicine’s end-to-end AI-powered… Read More

#News

#Biotechnology #Biotherapeutics #Clinical trials #Funding

Northwest Biotherapeutics announces $15 million financing    

Northwest Biotherapeutics, a biotechnology company developing DCVax personalised immune therapies for solid tumour cancers in the United States, has announced the closing of a $15 million financing.  The company plans to use the funding to help accelerate its activities related to its brain cancer programme.    The financing is in the form… Read More

#News

#Clinical trials #Drug development #Drug discovery #Tumours

FDA approves Avacta’s new cancer therapy drug

The US Food and Drug Administration (FDA) has approved Avacta’s Investigational New Drug (IND) application for AVA6000, which will allow the group to expand its Phase I clinical trial, ALS-6000-101, into clinical trial sites in the United States.  What is AVA6000?  AVA6000 is a novel form of… Read More

#Cancer Research #News

#Biopharmaceuticals #Biotechnology #Clinical trials #Covid-19 #Podcast

Clinical trials and the growing importance of technology: Podcast 

The latest sponsored DDW Sitting Down With podcast features Lisa Moneymaker and Paul O’Donohoe of Medidata and they talk to us about decentralised clinical trials. Medidata technology has helped to bring Covid-19 vaccines and treatments to market in record timelines and the company was the first to have launched a fully end-to-end Decentralised Clinical Trials (DCT) offering. Read More

#News